SOHO Brazil 2024

Videos
18:13

SOHO Brazil 2024

SOHO Brazil 2024: Treatment of Primary CNS Lymphoma

FEATURING Alvaro Alencar
  • 117 views
  • July 12, 2024
20:49

SOHO Brazil 2024

Summary of Recent Updates in Advanced Hodgkin Lymphoma

FEATURING Craig Moskowitz
  • 220 views
  • July 11, 2024
  • 2
27:26

SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

FEATURING Jeffrey Lancet
  • 539 views
  • July 11, 2024
  • 4
22:29

SOHO Brazil 2024

1L Therapy in CLL: What Are the Best Options?

FEATURING Jan Burger
  • 924 views
  • July 11, 2024
  • 2
13:22

SOHO Brazil 2024

Managing Infectious Complications With Bispecific and CAR-T Therapy in MM

FEATURING Noopur S. Raje
  • 203 views
  • July 11, 2024
  • 3
20:23

SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

FEATURING Noopur S. Raje
  • 432 views
  • July 11, 2024
  • 6
16:44

SOHO Brazil 2024

Frontline MM: Are Four Better Than Three?

FEATURING Noopur S. Raje
  • 84 views
  • July 11, 2024
  • 1
19:14

SOHO Brazil 2024

FL: How Do I Deal With Relapse?

FEATURING Brad Kahl
  • 510 views
  • July 11, 2024
  • 3
15:25

SOHO Brazil 2024

To 2L and Beyond: Treatment Options in R/R MCL

FEATURING Tycel Phillips
  • 40 views
  • July 11, 2024
20:01

SOHO Brazil 2024

FL Updates: Is There a Standard 1L Treatment?

FEATURING Brad Kahl
  • 331 views
  • July 11, 2024
  • 1
21:12

SOHO Brazil 2024

3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor

FEATURING Jan Burger
  • 569 views
  • July 11, 2024
  • 1
18:29

SOHO Brazil 2024

Single vs. Multiple Agents in 2L Therapy for CLL

FEATURING Jan Burger
  • 398 views
  • July 11, 2024
  • 2
19:21

SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

FEATURING Jeffrey Lancet
  • 600 views
  • July 11, 2024
  • 2
17:01

SOHO Brazil 2024

Are We Closer to Conquering HR-MDS?

FEATURING Rami Komrokji
  • 114 views
  • July 11, 2024
  • 3
21:26

SOHO Brazil 2024

Therapies on the Horizon in LR- and HR-MDS

FEATURING Rami Komrokji
  • 160 views
  • July 11, 2024
20:25

SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy in LBCL?

FEATURING Andrew Zelenetz
  • 63 views
  • July 11, 2024
14:17

SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We Treat Them?

FEATURING Andrew Zelenetz
  • 127 views
  • July 11, 2024
15:02

SOHO Brazil 2024

Summary of Updates in R/R DLBCL Treatment

FEATURING Alvaro Alencar
  • 110 views
  • July 11, 2024
22:11

SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

FEATURING Andrew Zelenetz
  • 616 views
  • July 11, 2024
  • 3
18:06

SOHO Brazil 2024

Summary of Recent Updates in R/R HL

FEATURING Craig Moskowitz
  • 133 views
  • July 11, 2024
  • 1
19:13

SOHO Brazil 2024

Summary of Recent Updates on LR-MDS Management

FEATURING Rami Komrokji
  • 52 views
  • July 11, 2024
19:52

SOHO Brazil 2024

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL in Adults

FEATURING Jan Burger
  • 130 views
  • July 11, 2024
  • 1
19:07

SOHO Brazil 2024

Early Stage HL: Can Radiation Therapy Be Eliminated?

FEATURING Craig Moskowitz
  • 115 views
  • July 11, 2024
38:54

SOHO Brazil 2024

PNH: Summary of Latest Advancements and Case Discussion

FEATURING Bruno Fattizzo
  • 257 views
  • July 11, 2024
  • 2
20:33

SOHO Brazil 2024

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

FEATURING Jeffrey Lancet
  • 144 views
  • July 11, 2024
17:30

SOHO Brazil 2024

Making Sense of 1L Treatment Options in MCL

FEATURING Tycel Phillips
  • 125 views
  • July 11, 2024
  • 1